Medpace

By default your notes are visible only to you.

291.2

52-week range

628.9

447.11

Your model inputs

Required return / cost of capital

FCFF terminal growth rate

Your fair value & Margin of safety

To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.

Forecast:

Valuation

Free Cash Flow Yield

FCF Yield TTM = Trailing Twelve Months free cash flow per share / current market price per share

5.6 %

Dividend Yield TTM

Market cap $

$ 12,769

Price / Earnings TTM

P/E TTM = current market price per share / Trailing Twelve Months diluted earnings per share

28.1

Price / Book TTM

21.3

PEG TTM

Price/Earnings-to-Growth ratio = P/E TTM divided by most recent annual diluted earnings per share growth rate

1.3

Earnings growth and return

LTM

5YR

10YR

Total return (price & dividends)

50.5 %

167.6 %

1,508.9 %

Free cash flow per share growth

29.2 %

283 %

1,052.6 %

Earnings per share growth

21 %

297.9 %

5,557.1 %

Founded: 1,992

Employees: 5,900

Business Summary:Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.

Fair Value Reference Estimate